The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.
Immunoglobulin replacement therapy (IRT) is the systematic care for patients with antibody deficit. Immunoglobulin replacement therapy can be of two types: subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). The choice of treatment depends upon numerous factors such as clinical symptoms, patient physiognomies, intravenous access, and possible side effects. However, subcutaneous immunoglobulin infusions for immunoglobulin replacement therapy (IRT) are more efficient, and these have a satisfactory safety profile along with good tolerance level.
Browse more detail information about Subcutaneous Immunoglobulin (SCIg) Market:
Advantages of the subcutaneous route include reduced adverse effects, partial deviation in peak and trough immunoglobulin (Ig) levels, decreased need for vascular access and improved patient autonomy. Subcutaneous immunoglobulin can be administered to most patients where clinically appropriate, and with pertinent learning and follow up care. These factors are likely to fuel the growth of the global subcutaneous immunoglobulin market.
Geographically, the global subcutaneous immunoglobulin market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America held the dominant share of the global market. Presence of key players and availability of subcutaneous immunoglobulin as well as rising adoption of advanced medical services has resulted in the dominance of this region. However, Asia Pacific is likely to grow at a substantial rate due to rise in primary immune deficiency in the region.
The global subcutaneous immunoglobulin market is characterized by the existence of a number of players. With all dealers competing to gain significant market shares, the market is very competitive in nature. Companies are competing on the basis of price and early approvals from the regulatory authorities such as the FDA.
Key players in the market include CSL Behring AG, Shire plc, Baxter International AG, Biotest AG, CUVITRU Baxalta US, Inc., Baxter Healthcare Corporation, Vivaglobin CSL, Hizentra CSL Behring AG, HYQVIA, and Behring GmbH.
Download sample copy of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20594
Immunoglobulin replacement therapy (IRT) is the systematic care for patients with antibody deficit. Immunoglobulin replacement therapy can be of two types: subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). The choice of treatment depends upon numerous factors such as clinical symptoms, patient physiognomies, intravenous access, and possible side effects.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453